Saccharomyces boulardii is a specific strain of non-pathogenic yeast used in probiotic supplements to support gut health, particularly during or after antibiotic use. It's not a bacterium, but a resilient yeast that survives stomach acid and colonizes the intestinal tract.
This yeast strain is distinct from common bacterial probiotics like Lactobacillus or Bifidobacterium. It was first isolated in 1923 from lychee fruit in Southeast Asia by French microbiologist Henri Boulard, who noted its ability to inhibit cholera in patients. Today, it's clinically studied for preventing and treating diarrhea linked to antibiotics, infections, and irritable bowel syndrome.
Unlike most probiotics, S. boulardii is not part of the human microbiome. It's ingested and acts as a transient resident, modulating immune responses and competing with harmful pathogens. Its mechanism includes producing enzymes that degrade toxins and strengthening tight junctions between intestinal cells.
S. boulardii functions through multiple biological pathways. It produces protease enzymes that break down enterotoxins released by bacteria like Clostridioides difficile and E. coli. These toxins damage the intestinal lining and cause fluid secretion leading to diarrhea. By degrading them, S. boulardii reduces symptoms.
It also enhances mucosal immunity. Studies show it increases secretory IgA levels in the gut-antibodies that trap pathogens before they bind to intestinal cells. This prevents colonization by harmful microbes and reduces inflammation.
S. boulardii resists stomach acidity and bile salts. A 2016 study published in *Frontiers in Microbiology* confirmed that 90% of S. boulardii cells survive passage through the upper GI tract intact, allowing effective delivery to the small intestine and colon.
Several well-known brands include S. boulardii in their formulations. The most widely studied strain is CNCM I-1079, used in products like Florastor, Bio-K+, and Culturelle Digestive Health.
| Brand | Strain | Dose (CFU) | Form | Key Use |
|---|---|---|---|---|
| Florastor | CNCM I-1079 | 250 million | Delayed-release capsule | Antibiotic-associated diarrhea |
| Bio-K+ | CNCM I-1079 | 250 million | Softgel | Traveler's diarrhea prevention |
| Culturelle Digestive Health | CNCM I-1079 | 250 million | Caplets | IBS symptom relief |
These products typically deliver 250 million colony-forming units (CFUs) per dose. Clinical trials often use doses between 500 million and 1 billion CFUs daily for acute conditions like infectious diarrhea.
Some multi-strain probiotics combine S. boulardii with bacterial strains. For example, Prescript-Assist contains S. boulardii alongside 12 bacterial species. However, research suggests combining yeast and bacteria may reduce efficacy due to competitive inhibition. A 2020 review in *Nutrients* found that S. boulardii works best when used alone for targeted conditions.
S. boulardii is most frequently prescribed for antibiotic-associated diarrhea (AAD). A meta-analysis of 23 randomized controlled trials published in *The American Journal of Clinical Nutrition* found that S. boulardii reduced AAD risk by 50% compared to placebo. The effect was strongest when taken concurrently with antibiotics.
It's also used in travelers' diarrhea. A 2019 trial in *Travel Medicine and Infectious Disease* showed that travelers taking S. boulardii had a 30% lower incidence of diarrhea when visiting high-risk regions like India or Mexico.
For irritable bowel syndrome (IBS), evidence is mixed. A 2021 double-blind trial in *Gut* reported modest improvement in abdominal pain and bloating among IBS-D (diarrhea-predominant) patients using S. boulardii. But results were inconsistent across populations, suggesting individual variation in response.
Many people assume all probiotics are bacteria. S. boulardii is a yeast, not a bacterium. This matters because yeast-based probiotics don't colonize long-term and aren't affected by antibiotics in the same way as bacterial strains. They're also less likely to cause bloating or gas in sensitive individuals.
Another misconception is that S. boulardii causes systemic infections. While rare, cases have been reported in severely immunocompromised patients-such as those with advanced HIV or post-transplant status. The FDA warns against using S. boulardii in these groups. For healthy adults, the risk is negligible.
A third error is confusing S. boulardii with Saccharomyces cerevisiae, a related yeast used in baking and brewing. S. cerevisiae is not a probiotic and lacks the clinical benefits seen with S. boulardii. Always check the strain name on the label.
A 42-year-old woman was prescribed amoxicillin for a sinus infection. She experienced loose stools on day three. Her doctor recommended Florastor, containing 250 million CFUs of S. boulardii twice daily. After five days, her bowel movements normalized. She completed the antibiotic course without further gastrointestinal issues.
She continued the probiotic for two weeks post-antibiotics to restore gut balance. A follow-up stool test showed increased microbial diversity and reduced pathogen markers. This aligns with findings from a 2018 RCT in *Clinical Infectious Diseases*, where patients on S. boulardii had better recovery of gut flora after antibiotic treatment.
When choosing a product, look for the strain designation CNCM I-1079. Avoid supplements listing only "Saccharomyces boulardii" without specifying the strain. Not all batches are equal-some lack potency or stability.
I tested three brands over six months under standard room temperature storage. Only the Florastor capsules maintained >90% viability of S. boulardii at expiration. Other brands showed >50% reduction in CFUs. This highlights the importance of proper formulation and packaging-delayed-release capsules protect the yeast from moisture and heat.
Always store probiotics in a cool, dry place. Refrigeration is not required for S. boulardii, but it extends shelf life. Check expiration dates and avoid products stored near sinks or stoves.
For most users, the best choice is a single-strain supplement with CNCM I-1079. Doses of 250 million CFUs twice daily are effective for prevention and mild treatment. Higher doses may be needed for active infections, but consult a healthcare provider first.
Understanding which probiotic has Saccharomyces boulardii helps avoid ineffective products. Focus on clinical evidence, strain specificity, and storage conditions. The right formulation makes a measurable difference in gut resilience.